Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.75 |
| ▸ | PPARD | Q03181 | 6/20 | 0.75 |
| ▸ | PPARA | Q07869 | 6/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.75 |
| ▸ | F7 | P08709 | 5/20 | 0.75 |
| ▸ | F3 | P13726 | 5/20 | 0.75 |
| ▸ | FABP4 | P15090 | 4/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.75 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.75 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.75 |
| ▸ | LMNA | P02545 | 3/20 | 0.75 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.75 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.75 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.75 |
| ▸ | HPGD | P15428 | 2/20 | 0.75 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.75 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3701659 | 1.00 | PPARG (0.75) | PPARGPPARDPPARAALDH1A1F7 | |
| SCHEMBL3693094 | 0.95 | PPARG (0.72) | PPARGPPARDPPARAALDH1A1F7 | |
| SCHEMBL28063983 | 0.95 | PPARG (0.72) | PPARGPPARDPPARAALDH1A1F7 | |
| SCHEMBL7503101 | 0.95 | PPARG (0.72) | PPARGPPARDPPARAALDH1A1F7 | |
| SCHEMBL3693092 | 0.95 | PPARG (0.72) | PPARGPPARDPPARAALDH1A1F7 | |
| SCHEMBL23466945 | 0.95 | PPARG (0.72) | PPARGPPARDPPARAALDH1A1F7 | |
| SCHEMBL28081722 | 0.93 | PPARG (0.70) | PPARGPPARDPPARAALDH1A1F7 | |
| SCHEMBL9149747 | 0.91 | ALDH1A1 (0.71) | PPARGPPARDPPARAALDH1A1F7 | |
| SCHEMBL28707040 | 0.91 | F7 (0.72) | PPARGPPARDPPARAALDH1A1F7 | |
| SCHEMBL9149751 | 0.91 | ALDH1A1 (0.71) | PPARGPPARDPPARAALDH1A1F7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081949-B1 | TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | GE HEALTHCARE DHARMACON INC (US) | 2014-12-10 | — | — | EP | disclosed |
| US-8809514-B2 | Tripartite oligonucleotide complexes and methods for gene silencing by RNA interference | GE HEALTHCARE DHARMACON, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8501706-B2 | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference | DHARMACON, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2064223-B1 | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference | DHARMACON INC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20120322855-A1 | Duplex Oligonucleotide Complexes and Methods for Gene Silencing by RNA Interference | DHARMACON, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-8252755-B2 | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference | DHARMACON, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20100093085-A1 | TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | DHARMACON, INC (US) | 2010-04-15 | — | — | US | disclosed |
| EP-2064223-A2 | DUPLEX OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | Dharmacon, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20080085869-A1 | Sense strand, antisense strand having complementarity to both the sense strand and a target gene, forming a duplex, a conjugate, facilitating cellular delivery, and a linker molecule; facilitates delivery to a cell, tissue or organism | DHARMACON, INC. (US) | 2008-04-10 | — | — | US | disclosed |
| WO-2008036825-A2 | DUPLEX OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | DHARMACON, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093085-A1 | TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | SNRPE, DCLRE1B, RNASE1 | PPARG 4504/4885PPARD 4734/4885PPARA 4354/4885 |
| US-20120322855-A1 | Duplex Oligonucleotide Complexes and Methods for Gene Silencing by RNA Interference | SNRPE, AGO2, DCLRE1B | PPARG 4264/4885PPARD 4554/4885PPARA 4096/4885 |
| US-20080085869-A1 | Sense strand, antisense strand having complementarity to both the sense strand and a target gene, forming a duplex, a conjugate, facilitating cellular delivery, and a linker molecule; facilitates delivery to a cell, tissue or organism | SRRT, SNRPE, SSBP1 | PPARG 4559/4885PPARD 4688/4885PPARA 4196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.